18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
21:24 , May 11, 2017 |  BC Innovations  |  Translation in Brief

Going universal

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell...